Information for the public
What has NICE said?
Bosutinib (Bosulif) is recommended as a possible treatment for adults with chronic myeloid leukaemia when:
the leukaemia is Philadelphia chromosome positive
they have previously had 1 or more tyrosine kinase inhibitor (drugs that slow or stop cancer growth) and
the anticancer drugs imatinib, nilotinib and dasatinib are not appropriate.
If you have chronic myeloid leukaemia, and your doctor thinks that bosutinib is the right treatment, you should be able to have it on the NHS.
Bosutinib should be available on the NHS within 3 months.
Chronic myeloid leukaemia is a cancer of a type of white blood cell (called myeloid cells). These cells multiply in an uncontrolled way and stop other blood cells working properly. Most people with chronic myeloid leukaemia have an abnormal chromosome called the Philadelphia chromosome in their cancer cells (known as Philadelphia chromosome positive disease).
Bosutinib blocks a protein called tyrosine kinase inside the cancer cells, helping to slow or stop the cancer growing for a time.
NHS Choices may be a good place to find out more.
These organisations can give you advice and support:
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.